Recently, two additional molecules (GSK591 and LLY-283) have been identified as potent inhibitors of PRMT5 in GBM patient-derived cancer stem cell lines, resulting in altered splicing and impaired clonogenic capacity [205]. This evidence concerns the gene PRMT5 and glioblastoma.